Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
6(60%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
5
50%
Ph phase_2
3
30%
Ph phase_3
1
10%

Phase Distribution

5

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
5(55.6%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

10

all time

Status Distribution
Active(8)
Completed(1)
Other(1)

Detailed Status

Recruiting5
Not yet recruiting2
Completed1
unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
6
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (55.6%)
Phase 23 (33.3%)
Phase 31 (11.1%)

Trials by Status

completed110%
not_yet_recruiting220%
recruiting550%
unknown110%
active_not_recruiting110%

Recent Activity

6 active trials
Showing 5 of 10
completedphase_1

Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma

NCT07529613
recruitingphase_1

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

NCT04686305
recruitingphase_2

Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

NCT07371585
not_yet_recruitingphase_2

SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

NCT07417241
recruitingphase_1

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

NCT06244485
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07529613Phase 1

Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma

Completed
NCT04686305Phase 1

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Recruiting
NCT07371585Phase 2

Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

Recruiting
NCT07417241Phase 2

SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

Not Yet Recruiting
NCT06244485Phase 1

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Recruiting
NCT06174987Phase 3

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Recruiting
NCT07134153Phase 1

Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases

Recruiting
NCT05765851Phase 1

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

Active Not Recruiting
NCT06548178Phase 2

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

Not Yet Recruiting
NCT06135194

Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10